About the Oncotype MAP Pan-Cancer Tissue Test (Oncology)

Providing answers physicians need at the speed patients deserve

With the rise of precision oncology, genomic profiling is playing an increasingly large role in clinical decision making and bringing clarity to targeted treatment approaches. Across all advanced cancer types, faster answers are needed.

Fast, actionable insights bring clarity to treatment options

The Oncotype MAP Pan-Cancer Tissue test delivers rapid, comprehensive tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. The test identifies actionable genomic alterations within 3-5 business days^*† to guide timely treatment decisions, usually before the next follow up visit.

Utilizing next generation sequencing (NGS) and a broad array of immunohistochemical (IHC) stains and panels, the Oncotype MAP Pan-Cancer Tissue test identifies clinically-relevant genomic alterations from patient specimens as small as 3 mm² of tissue^‡ with 15% tumor content, about the size of a grain of rice. Fewer Quantity Not Sufficient (QNS) samples mean more of your patients get tested and treated.

Why Choose the Oncotype MAP Pan-Cancer Tissue Test?

The Oncotype MAP Pan-Cancer Tissue test can provide in-depth insights into alterations of hundreds of cancer-related genes, usually before the patient’s next follow-up visit.

Patient Eligibility

The Oncotype MAP Pan-Cancer Tissue test is most appropriate for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. The test can also provide valuable data and analysis to inform treatment decisions where no standard of care exists.

LEARN MORE ABOUT ELIGIBILITY

Interpreting the Report

Results are provided in an easy-to-interpret report with NCCN actionable indications for therapy, along with potential evidence-based therapies and clinical trials, to deliver treatment options for a breadth of solid tumor types.

The Oncotype MAP Pan-Cancer Tissue Test profiles a wide range of genetic structures including:

• Single nucleotide variants (SNVs) and insertions/deletions in coding regions of the genes listed below
• Untranslated regions (UTRs) and splice junctions when actionable, e.g. MET exon 14 skipping and EGFRvIII
• Microsatellite instability (MSI)
• Tumor mutational burden (SNVs, insertions, deletions) based on -1 megabase
• Select fusions involving ALK, BRAF, FGFR1, FGFR2, FGFR3, MET, RET, ROS1, NTRK1, NTRK2, NTRK3 (ETV6)
• Copy number variants

VIEW 257 GENE NGS PANEL 257 Gene NGS Panel ABCB1 ABCC1 ABCC2 ABL1 ACVR1 ACVR1B ACVR2A ACVR2B ACVRL1 ADAMTS1 ADAMTS6 ADAMTS9 ADAMTS16 ADAMTS18 ADAMTSL1 AKT1 AKT2 AKT3 ALK AMER1 APC APLNR AR ARAF AREG ARID1A ARID1B ARID2 ATM ATR ATRX AURKA AURKB AXIN1 AXL B2M BAP1 BARD1 BCOR BMP6 BMPR1A BMPR1B BNIP3 BRAF BRCA1 BRCA2 BRIP1 BTK BUB1B CALR CBL CCND1 CCND2 CCND3 CCNE1 CD274 CDA CDC73 CDH1 CDK4 CKD6 CDK12 CDKN2A CHEK1 CHEK2 CHFR CHKA CIC CREBBP CSF1R CTLA4 CTNNB1 CYP19A1 CYP1A1 CYP2D6 CYP3A4 CYSLTR2 DCK DDR2 DICER1 DNMT3A EGFR EMSY EP300 EPCAM EPHA5 EPHA7 ERBB2 ERBB3 ERBB4 ERCC1 ERCC2 ERCC3 ERRFI1 ESR1 ESR2 EWSR1 EZH2 FAM175A FANCA FANCC FANCD2 FANCE FANCF FANCG FANCM FAT1 FBXW7 FCGR2A FGD4 FGF3 FGF4 FGFR1 FGFR2 FGFR3 FGFR4 FLT3 FLT4 FOXL2 FUBP1 GAS6 GATA3 GLI1 GNA11 GNAQ GNAS GSTP1 HAMP HDAC2 HGF HNF1A HRAS HSD3B1 IDH1 IDH2 IGF1R IKZF1 IL6R JAK1 JAK2 JAK3 KDM5C KDM6A KDR KEAP1 KIT KRAS MAF MAP2K1 MAP2K2 MAP3K1 MAPK1 MAPK3 MAPKAPK5 MDM2 MDM4 MED12 MEN1 MET MGMT MLH1 MPL MRE11A MSH2 MSH6 MTHFR MTOR MUTYH MYC MYCN MYOD1 NBN NF1 NF2 NFE2L2 NOTCH1 NOTCH2 NOTCH3 NPMI NRAS NTRK1 NTRK2 NTRK3 PALB2 PBRM1 PDCD1LG2 PDGFRA PDGFRB PIK3CA PIK3CB PIK3CD PIK3CG PIK3R1 PIM1 PLCB4 PLCG1 PMS2 POLD1 POLE PP2R1A PTCH1 PTEN PTPN11 RAD50 RAD51C RAD51D RAF1 RB1 RBM10 RECQL RET RHEB RICTOR RIT1 RNF43 ROS1 RPTOR RRMI SDHB SDHC SETD2 SF3B1 SMAD1 SMAD2 SMAD4 SMAD5 SMAD9 SMARCA4 SMARCB1 SMO SOCS1 SPOP STAG2 STAT3 STAT5A STAT5B STK11 SUFU TERT-p TGFB1 TGFB2 TGFB3 TGFBR1 TGFBR2 TNFA1P3 TNK1 TOP2A TP53 TSC1 TSC2 TSHR TYMS VEGFA VHL WTI XRCC1 YES1 VIEW SINGLE IHC STAINS -and- TUMOR-SPECIFIC IHC PANELS Single IHC Stains MMR Panel ALK AR CAIX ER hENTI HER2 IDO MET MGMT PD1 PD-L1 (22C3) PD-L1 (SP142) PR PTEN ROS1 TOP1 TP TRKpan TS TUBB3 MLH1 MSH2 MSH6 PMS2 Tumor-Specific Panels Anal Carcinoma: PD-L1 (22C3), PD-1, TS, TUBB3 Appendix: HER2, PD-L1 (22C3), TOP1, PTEN Bladder: PD-L1 (22C3), PD-L1 (SP142), hENTI, TUBB3 Bone Cancer: TOP1, MGMT, CAIX, HENTI Breast: AR, PD-L1(SP142), PD-L1 (22C3), TP CNS / Brain Cancers: MGMT, CAIX, TUBB3, TOP1 Cervical: PD-L1 (22C3), CAIX, hENTI, TOP1 Colorectal: HER2, PD-L1 (22C3), TOP1, PTEN, TS Gastric / Esophageal: HER2, PD-L1 (22C3), PTEN, TS GIST: PD-L1 (22C3), MET Head and Neck: PD-L1 (22C3), CAIX, TUBB3, PTEN Head and Neck Salivary Gland: HER2, AR, CAIX, PTEN Hepatobillary / Cholangiocarcinoma: hENTI, HER2, TP, PD-L1 (22C3) Hepatobillary / Gallbladder: hENTI, HER2, PD-L1 (22C3), TOP1 Hepatobillary / Hepatocellular: hENTI, PD-L1 (22C3), CAIX, MET Kidney: PD-L1 (22C3), MET, CAIX, hENTI Melanoma: PD-L1 (22C3), MGMT, PTEN, TUBB3 Mesothelioma: PD-L1 (22C3), TS, hENTI, TUBB3 MMR: MLH1, MSH2, MSH6, PMS2 Neuroendocrine: PD-L1 (22C3), MGMT, PTEN, TP NSCLC: PD-L1 (22C3), ALK, PD-L1 (SP142), PTEN, TS Ovarian: ER, HER2, TOP1, TUBB3 Pancreatic: hENTI, PTEN, TP, TOP1 Penile Cancer: PD-L1 (22C3), TP, CAIX, TUBB3 Prostate: AR, PTEN, TUBB3, PD-L1 (22C3) Sarcoma: CAIX, TUBB3, TOP1, MGMT SCLC: PD-L1 (22C3), TOP1, MGMT Small Bowel: TOPO1, CAIX, TUBB3, hENTI Testicular Cancer: PD-L1 (22C3), TUBB3, hENTI Thyroid: PD-L1 (22C3), ALK, TUBB3, CAIX Thymoma / Thymic Carcinoma: PD-L1 (22C3), TUBB3, hENTI, TS Uterine: PD-L1 (22C3), HER2, MGMT, TUBB3 Uveal Melanoma: PD-L1 (22C3), MGMT, TUBB3 Vulvar Cancer: PD-L1 (22C3), CAIX, TUBB3, hENTI Other Solid Tumors: PD-L1 (22C3), HER2, TOP1, PTEN, TS

EXPLORE NSCLC SAMPLE REPORT

Oncotype MAP Pan-Cancer Tissue test focuses on therapy selection for today and captures emerging markers that may find their way into guidelines tomorrow.

ORDER NOW